Shanghai,June 16, 2026 – During CPHI & PMEC China 2026, the “Oligonucleotide Drug R&D and Innovation Symposium” was successfully convened, bringing together leading experts to explore the rapidly advancing field of oligonucleotide-based medicines. As the third major class of innovative drugs, oligonucleotide therapeutics hold the promise of targeting previously “undruggable” targets and demonstrate outstanding potential across a broad range of disease areas, positioning them at the forefront of biomedical innovation.

Dr. H Fai Poon, Chief Executive Officer of Sirnaomics, was invited to host a keynote roundtable discussion at the symposium. During the session, Dr. Poon disclosed that two of Sirnaomics’ in-house AI-driven R&D programs have entered application testing, while the Company is actively constructing a proprietary AI-powered research and development platform. Artificial intelligence is currently being trialed in drug molecule design, model construction, and target screening. Leveraging this platform is expected to markedly reduce trial-and-error costs and significantly streamline the R&D process. Drawing on Sirnaomics’ corporate practice, Dr. Poon also engaged with fellow industry experts to discuss end-to-end development strategies for RNA therapeutics spanning from discovery to commercialization, sharing a wealth of practical, actionable insights.

[Image: Dr. H Fai Poon, CEO of Sirnaomics]

The symposium served to further strengthen the entire RNA drug industry chain. Looking ahead, Sirnaomics will continue to accelerate the build-out of its AI platform, join forces with industry partners to advance the field, and ultimately deliver innovative therapies to patients faster.

About Sirnaomics

Sirnaomics Ltd.(HK: 2257), known as Asia's "First RNAi Therapeutics Stock," is a clinical-stage global biopharmaceutical company specializing in RNA interference technology. Utilizing its dual core technology platforms and diverse pipeline, the company is at the forefront of developing RNAi therapies to drive industry growth.

Sirnaomics has two proprietary delivery platforms:

1. Polypeptide Nanoparticle (PNP) Platform: An extrahepatic delivery platform enabling precise targeting of tissues such as skin, adipose tissue, and muscle.
2. GalAhead™ Delivery Platform: A liver-targeted delivery system with clear IP and long-acting administration capabilities.

The company is also an industry leader with its innovative linker-free, dual-target RNAi technology. Sirnaomics' robust pipeline addresses oncology, local fat reduction, medical aesthetics, and cardiovascular diseases, with multiple products in clinical trials. Beyond its internal development, Sirnaomics embraces an open-collaboration strategy, integrating its technology platforms to support the broader industry and benefit patients worldwide.